Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Have a great Sunday, especially those of you like me that are celebrating Orthodox Easter ... As well as those of you who are also like me and mourning another Maple Leafs Game 7 exit ... Ugggh!

Sincerely,

George et al

Message: Trials

Summer Street must have missed this part of the call:

.

.

In summary, the 171 trial met the primary efficacy endpoint of non-inferior reduction in A1c when comparing AFREZZA -Gen2 to insulin aspart as well as the primary safety endpoint of showing a comparable mean change in FEV1 over the treatment period between the Gen2 and the MedTone treatment groups.

Share
New Message
Please login to post a reply